EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS

被引：0
|
作者：
Tuttle, Katherine
Cherney, David
Hadjadj, Samy
Idorn, Thomas
Mosenzon, Ofri
Perkovic, Vlado
Rasmussen, Soren
Wolthers, Benjamin
Bain, Stephen C.
机构：
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2020年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
MO051
引用
收藏
页码：152 / 152
页数：1
相关论文
共 50 条
  • [21] Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials
    Verma, Subodh
    Bain, Stephen C.
    Fries, Tea Monk
    Mazer, C. David
    Nauck, Michael A.
    Pratley, Richard E.
    Rasmussen, Soren
    Saevereid, Hans A.
    Zinman, Bernard
    Buse, John B.
    DIABETES OBESITY & METABOLISM, 2019, 21 (07): : 1745 - 1751
  • [22] Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
    Husain, Mansoor
    Bain, Stephen C.
    Holst, Anders Gaarsdal
    Mark, Thomas
    Rasmussen, Soren
    Lingvay, Ildiko
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
  • [23] CHANGE IN KDIGO KIDNEY RISK CATEGORY WITH SEMAGLUTIDE TREATMENT-A POST HOC ANALYSIS OF THE SUSTAIN 6 TRIAL
    Tuttle, Katherine
    Bain, Stephen C.
    Cherney, David
    Lawson, Jack
    Rasmussen, Soren
    Vrhnjak, Blaz
    Khunti, Kamlesh
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I331 - I331
  • [24] Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
    Mansoor Husain
    Stephen C. Bain
    Anders Gaarsdal Holst
    Thomas Mark
    Søren Rasmussen
    Ildiko Lingvay
    Cardiovascular Diabetology, 19
  • [25] DURATION OF DIABETES AND CARDIORENAL EFFICACY OF LIRAGLUTIDE AND SEMAGLUTIDE: A POST HOC ANALYSIS OF THE LEADER AND SUSTAIN-6 CLINICAL TRIALS
    Verma, Subodh
    Bain, Stephen C.
    Honore, Julie Broe
    Fries, Tea Monk
    Nauck, Michael A.
    Pratley, Richard E.
    Rasmussen, Soren
    Zinman, Bernard
    Buse, John
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1704 - 1704
  • [26] Neutrophil to lymphocyte ratio predicts cardiovascular events in people with type 2 diabetes: Post hoc analysis of the SUSTAIN 6 and PIONEER 6 cardiovascular outcomes trials
    Verma, Subodh
    Husain, Mansoor
    Madsen, Christian M.
    Leiter, Lawrence A.
    Kuhlman, Anja Birk
    Vilsboll, Tina
    Rasmussen, Soren
    Libby, Peter
    DIABETES OBESITY & METABOLISM, 2023, 25 (08): : 2398 - 2401
  • [27] Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial
    Tuttle, Katherine R.
    Bain, Stephen C.
    Bosch-Traberg, Heidrun
    Khunti, Kamlesh
    Rasmussen, Soren
    Sokareva, Ekaterina
    Cherney, David Z.
    KIDNEY INTERNATIONAL REPORTS, 2024, 9 (07): : 2006 - 2015
  • [28] Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial
    Wang, Jingyu
    Yang, Juhong
    Jiang, Wenhui
    Liu, Wenyan
    Shen, Zewei
    Gao, Zhongai
    Chang, Baocheng
    DIABETES OBESITY & METABOLISM, 2024,
  • [29] SUSTAIN 6: A POST-HOC ANALYSIS OF THE EFFECT OF SEMAGLUTIDE ON CARDIOVASCULAR OUTCOMES OVER TIME IN SUBJECTS WITH TYPE 2 DIABETES
    Bellary, S.
    Jodar, E.
    Seufert, J.
    Damgaard, L. H.
    Holst, A. Gaarsdal
    Leiter, L.
    ATHEROSCLEROSIS SUPPLEMENTS, 2018, 34 : E6 - E7
  • [30] SUSTAIN 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes
    Jodar, E.
    Seufert, J.
    Damgaard, L. H.
    Holst, A. G.
    Leiter, L. A.
    EUROPEAN HEART JOURNAL, 2017, 38 : 819 - 819
12345